IS5101A - Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð - Google Patents

Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð

Info

Publication number
IS5101A
IS5101A IS5101A IS5101A IS5101A IS 5101 A IS5101 A IS 5101A IS 5101 A IS5101 A IS 5101A IS 5101 A IS5101 A IS 5101A IS 5101 A IS5101 A IS 5101A
Authority
IS
Iceland
Prior art keywords
cd40l
antibody
context
resistant
methods
Prior art date
Application number
IS5101A
Other languages
English (en)
Inventor
L. Kalled Susan
W. Thomas David
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of IS5101A publication Critical patent/IS5101A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS5101A 1997-01-10 1999-06-30 Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð IS5101A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (en) 1997-01-10 1998-01-09 Methods of therapeutic administration of anti-cd40l compounds

Publications (1)

Publication Number Publication Date
IS5101A true IS5101A (is) 1999-06-30

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5101A IS5101A (is) 1997-01-10 1999-06-30 Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð

Country Status (21)

Country Link
US (2) US20020071840A1 (is)
EP (1) EP0966302B1 (is)
JP (1) JP2001508450A (is)
KR (2) KR100632846B1 (is)
CN (1) CN1248921A (is)
AT (1) ATE356634T1 (is)
AU (1) AU721697B2 (is)
BR (1) BR9807471A (is)
CA (1) CA2277223A1 (is)
CZ (1) CZ244399A3 (is)
DE (1) DE69837322T2 (is)
EA (1) EA001426B1 (is)
EE (1) EE9900275A (is)
HK (1) HK1024424A1 (is)
IL (1) IL130785A0 (is)
IS (1) IS5101A (is)
NO (1) NO993275L (is)
NZ (1) NZ337073A (is)
PL (1) PL193966B1 (is)
TR (1) TR199902192T2 (is)
WO (1) WO1998030241A1 (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EA002549B1 (ru) * 1997-05-17 2002-06-27 Байоджен, Инк. Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантата
EP1034001B1 (en) * 1997-06-20 2004-08-04 Biogen Idec MA Inc. Cd154 blockade therapy for therapeutic protein inhibitor syndrome
WO2000016801A1 (en) * 1998-09-21 2000-03-30 Genetics Institute, Inc. Methods of downmodulating the immune response to therapeutic proteins
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
US20030170231A1 (en) * 2000-03-06 2003-09-11 Toshihiko Yamauchi Remedies and preventives for antiphospholipid antibody syndrome
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CA2781858C (en) 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
DK1562571T3 (da) * 2002-11-21 2011-12-05 Genzyme Corp Kombination af et diamidderivat og immunsuppressive midler til hæmning af transplantatafstødning
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ATE188487T1 (de) * 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
CN1137726C (zh) * 1993-09-02 2004-02-11 达特茅斯学院理事 延长体液免疫抑制的方法
ATE267607T1 (de) * 1993-12-23 2004-06-15 Immunex Corp Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations

Also Published As

Publication number Publication date
EP0966302A1 (en) 1999-12-29
EA001426B1 (ru) 2001-02-26
HK1024424A1 (en) 2000-10-13
NZ337073A (en) 2001-01-26
US20050158314A1 (en) 2005-07-21
CN1248921A (zh) 2000-03-29
EE9900275A (et) 2000-02-15
AU5735398A (en) 1998-08-03
KR100632846B1 (ko) 2006-10-16
NO993275L (no) 1999-09-09
CZ244399A3 (cs) 1999-10-13
NO993275D0 (no) 1999-07-01
DE69837322T2 (de) 2007-11-22
EA199900633A1 (ru) 2000-02-28
IL130785A0 (en) 2001-01-28
AU721697B2 (en) 2000-07-13
US20020071840A1 (en) 2002-06-13
DE69837322D1 (de) 2007-04-26
WO1998030241A1 (en) 1998-07-16
ATE356634T1 (de) 2007-04-15
PL334500A1 (en) 2000-02-28
PL193966B1 (pl) 2007-04-30
BR9807471A (pt) 2000-03-21
JP2001508450A (ja) 2001-06-26
EP0966302B1 (en) 2007-03-14
CA2277223A1 (en) 1998-07-16
TR199902192T2 (xx) 1999-12-21
KR20050088494A (ko) 2005-09-06
KR20000070035A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
IS5101A (is) Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð
MY169308A (en) Treatment of tnf? related disorders
HK1084689A1 (en) Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
PL375041A1 (en) Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
NO20045056L (no) Fremgangsmater for behandling av hepatitt
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
IL192287A0 (en) Pharmaceutical compositions and methods for use
DE69739970D1 (de) Methode zur behandlung sexueller fehlfunktionen
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
ATE302011T1 (de) PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
DK1244442T3 (da) Fremgangsmåde til bestemmelse af nukleotidsynteseinhibitorer med færre bivirkninger